Peer-reviewed veterinary case report
Toceranib treatment results in 42 dogs with thyroid cancer
By Sheppard-Olivares, Sabina et al.·Published in Veterinary and comparative oncology·2020·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
- Species:
- dog
Plain-English summary
A group of 42 dogs diagnosed with thyroid cancer were treated with a medication called toceranib phosphate. This treatment showed positive results, with about 88% of dogs that had not received prior therapy experiencing clinical benefits, and 75% of those who had been treated before also improving. The dogs that started treatment without symptoms lived an average of 563 days, while those who had previous treatments lived about 1082 days. Overall, toceranib phosphate appears to be a promising option for managing thyroid cancer in dogs, with minimal side effects reported.
People also search for: dog thyroid cancer treatment · toceranib phosphate for dogs · canine thyroid carcinoma survival rate
Abstract
Thyroid carcinoma is the most common endocrine malignancy in dogs. Thyroidectomy and radiation therapy control local disease, yet are not always feasible, and efficacious medical therapies need to be identified. Toceranib phosphate has been reported to provide clinical benefit (CB) in dogs with thyroid carcinoma, while its role in treatment-naïve thyroid tumours has not been well-described. The objective of this study was to describe the use of toceranib in the management of thyroid carcinomas in dogs in both the naïve-disease and prior therapy- settings. A medical record search identified 42 dogs diagnosed with thyroid carcinoma and treated with toceranib, of which 26 and 16 dogs were in settings of naïve-disease and after prior therapy, respectively. Twenty-three (88.4%) and twelve (75%) dogs experienced CB in the naïve and prior therapy settings, respectively. The median [95% confidence interval] progression free interval (PFI) for dogs in the naïve and prior therapy settings were 206 [106,740] and 1015 [92,1015] days, respectively. The median overall survival time (OST) for dogs in the naïve and prior therapy settings were 563 [246,916] and 1082 [289,1894] days, respectively. Overall, the data provided no evidence for differences in overall PFI (P > .20) or OST (P = .15) between settings. However, when asymptomatic at the time of diagnosis, dogs in the naïve setting showed poorer survival prognosis (estimated hazard ratio 17.2 [1.8, 163]) relative to dogs in the prior therapy setting. This study characterizes PFI, OST and CB with minimal AE in dogs with thyroid carcinoma treated with toceranib in both the naïve and prior therapy settings.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32012432/